QURE Investor ALERT: Block & Leviton Investigating uniQure for Securities Fraud; Investors Should Contact the Firm to Potentially Recover Losses

Core Viewpoint - UniQure N.V. is under investigation for potential securities law violations following a significant drop in its stock price after the FDA deemed its clinical data for an experimental gene therapy insufficient [2][4]. Group 1: Company Overview - UniQure's shares fell by as much as 66% after the FDA's announcement regarding its gene therapy for Huntington's disease [2]. - The FDA's decision represents a considerable shift from previous communications between the regulator and UniQure [2]. Group 2: Investigation Details - Block & Leviton is investigating UniQure's disclosures to determine if there were any violations of securities laws [4]. - The firm is reaching out to investors who have lost money in their UniQure investments to discuss potential recovery options [1][3]. Group 3: Investor Actions - Investors who purchased UniQure common stock and experienced a decline in share value may be eligible to participate in the investigation [3]. - Block & Leviton encourages affected investors to contact them for more information on recovery [5][7].